PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
2008
PPARδ Agonism for Obesity Treatment: Challenges and Opportunities
publication
Evidence: moderate
Author Information
Author(s): Mylène Perreault, David V. Erbe, James F. Tobin
Primary Institution: Wyeth Research
Hypothesis
Can PPARδ agonists provide a viable treatment option for obesity and its associated disorders?
Conclusion
PPAR modulators, particularly PPARδ agonists, show promise for treating obesity and improving metabolic health despite significant development challenges.
Supporting Evidence
- Obesity rates have tripled in developing countries over the last two decades.
- Current obesity treatments provide limited weight loss and have undesirable side effects.
- PPARδ agonists could improve metabolic parameters and induce weight loss.
Takeaway
This study talks about a special type of medicine that might help people lose weight and feel better if they are overweight. It has some challenges, but it could be a good option for many people.
Limitations
The development of PPAR modulators faces challenges such as differences in PPAR biology between species and potential side effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website